IDYA Ideaya Biosciences Inc
Company Analysis
Latest News
🟢 Ideaya Biosciences is trading 12% up in after-hours trading
Ideaya Biosciences is trading at $39.77, up 12.11% in after-hours trading; no specific announcement explaining the October 21 move was identified. - The...
🟢 Ideaya Biosciences rises 4.0% — Biotech Sector Surges on M&A Activity and Positive Clinical Trial Data
With Biotech (XBI) up 2.1%, this looks like a sector-led move rather than a company-specific surprise. The biotechnology sector is experiencing a significant...
🔴 Ideaya Biosciences is trading 4.31% down amid broader biotech weakness
Ideaya Biosciences is trading at $34.51, down 4.31%, during the October 13 session; no clear company-specific announcement explaining the decline surfaced in...
🔴 Ideaya Biosciences is trading 4.18% down today as biotech stocks decline
Ideaya Biosciences is trading 4.18% down at $36.47, with biotech-sector weakness the clearest available explanation. - Biotech stocks are broadly lower, with...
🟢 Ideaya Biosciences is trading 4.4% up today amid CSO's promotion to President, Research and Development
Ideaya Biosciences is trading 4.4% up at $38.31 alongside same-day leadership news, though available reporting does not link it to the gain. - On September 28,...
🔴 Ideaya Biosciences is trading 4.24% down today amid broad risk-off trading and biotech weakness
Ideaya Biosciences is trading at $35.87, down -4.24%, as broad risk-off trading and weaker biotechnology sentiment weigh on shares. - Nasdaq is down 0.87%,...
🔴 Ideaya Biosciences is trading 4.12% down today on higher oil prices and Treasury yields
Ideaya Biosciences is trading 4.12% down at $38.08 as U.S. equities weaken amid higher oil prices and Treasury yields. - The Nasdaq Composite is down 1.04%,...
🟢 Ideaya Biosciences is trading 8.29% up in pre-market as biotech ETF XBI gains 2.61%
Ideaya Biosciences is trading at $43.00, up 8.29%, with biotech-sector momentum the strongest identifiable explanation; no clear company-specific catalyst has...
🔴 Ideaya Biosciences is trading 18.53% down in after-hours trading with no clear company-specific catalyst identified
Ideaya Biosciences is trading at $32.35, down 18.53%, with no clear company-specific catalyst identified for the after-hours decline on September 22, 2026. -...
🔴 Ideaya Biosciences is trading 21.3% down in after-hours trading with no clear company-specific catalyst identified
Ideaya Biosciences is trading 21.3% down in after-hours trading at $30.23 after closing at $38.41 on September 18, 2026; no clear company-specific catalyst has...
🟢 Ideaya Biosciences rises 4.0% — Biotech Sector Rallies on Strong Industry Outlook and M&A Optimism
With Biotech (XBI) up 2.5%, this looks like a sector-led move rather than a company-specific surprise. The biotechnology sector, as measured by the XBI ETF,...
Ideaya Biosciences Doses First Patient in Global Phase 3 Registrational Trial for Uveal Melanoma Treatment
IDEAYA Biosciences, in partnership with Servier, announced it has dosed the first patient in its OptimUM-11 global Phase 3 registrational trial. The study is...
🔴 Ideaya Biosciences falls 4.0% — Biotech Sector Declines Amid Fed Rate Hike Fears
With Biotech (XBI) down 2.3%, this looks like a sector-led move rather than a company-specific surprise. The biotech sector, as measured by the XBI ETF, fell...
BlackRock Discloses New 10.12% Stake in Ideaya Biosciences
Ideaya Biosciences saw significant new institutional investment, according to SEC filings reported on August 27, 2026. BlackRock Inc. acquired a new stake in...
Deerfield Management boosts IDEAYA Biosciences stake by 77%
Healthcare investment firm Deerfield Management significantly increased its position in IDEAYA Biosciences (IDYA), a precision oncology company, by over 77%....
IDEAYA and Genentech Partner on Pancreatic Cancer, Targeting Rare Genetic Mutations
IDEAYA Biosciences and Genentech, a Roche Group member, have launched a clinical collaboration to evaluate a combination therapy for pancreatic cancer. The...
🔴 Ideaya Biosciences is trading 5% down in pre-market — catalyst unclear
Ideaya Biosciences is trading 5% down at $34.50 after falling from the August 14 close of $36.30, with the catalyst unclear. - No clear company-specific...
Ideaya Biosciences Inc Q2 2026 Earnings Preview: What Analysts Expect on August 04, 2026
Ideaya Biosciences is projected to report a Q2 2026 loss of $1.18 per share on revenue of $7.40 million, with the current stock price of $35.50 trading at a...
Ideaya Biosciences Expands IDE892 Cancer Trial, Reaches Target Exposure Levels
Ideaya Biosciences initiated the Part 2 monotherapy expansion of its Phase 1/2 clinical trial for IDE892. This PRMT5 inhibitor targets MTAP-deleted solid...
🟢 Ideaya Biosciences rises 4.3% — Biotech Sector Rallies on Blockbuster M&A Deal and Positive Trial Data
With Biotech (XBI) up 2.3%, this looks like a sector-led move rather than a company-specific surprise. The biotechnology sector is experiencing a significant...